Gilead Expands Deal and Triples Tango Targets to 15
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 8 (Table of Contents)
Published: 26 Aug-2020
DOI: 10.3833/pdr.v2020.i8.2558 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Continuing to invest in its immuno-oncology portfolio, Gilead Sciences has agreed to expand its collaboration with Tango Therapeutics to increase the number of targets from five to 15...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS